共 90 条
[1]
Abrams WB, Clinical Pharmacology and Therapeutics, 50, (1991)
[2]
Adaon J.W., Vapnek D., Recombinant erythropoietin to improve athletic performance, New England Journal of Medicine, 324, (1991)
[3]
Alderman M.H., Which antihypertensive drug first - and why!, Journal of the American Medical Association, 267, pp. 2786-2787, (1992)
[4]
Bienz-Tadmor B., DiCerbo P.A., Tadmor G., Lasagna L., Biopharmaceuticals and conventional drugs: clinical success rates, Biotechnology, 10, pp. 521-525, (1992)
[5]
Branch R.A., Johnston P.E., Koestner J.A., Bluhm R., Stratton C.W., Et al., The formulary: an educational tool for clinical pharmacology, Clinical Pharmacology and Therapeutics, 51, pp. 481-488, (1992)
[6]
Brooks D.D., Smith D.R., Anderson R.J., Medical apartheid: an American perspective, Journal of the American Medical Association, 266, pp. 2746-2749, (1991)
[7]
Burstall M.L., The transparency directive: is it working?, PharmacoEconomics, 1, pp. 1-8, (1992)
[8]
Byar D.P., Shoenfeld D.A., Green S.B., Amato D.A., Davis R., Et al., Design considerations for AIDS trials, New England Journal of Medicine, 323, pp. 1343-1348, (1990)
[9]
Promoting health or pushing drugs?, (1992)
[10]
Collins R., Julian D., British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction, British Heart Journal, 66, pp. 250-255, (1991)